Skip to main content
SpringerLink
Log in

Selectivity of HIF-PH inhibitors: concerns regarding possible off-target effects

  • Letter to the editor
  • Published:
Clinical and Experimental Nephrology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Maxwell PH, Eckardt KU. HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond. Nat Rev Nephrol. 2016;12:157–68 (see the supplementary Table 1).

  2. Salo AM, Myllyharju J. Prolyl and lysyl hydroxylases in collagen synthesis. Exp Dermatol. 2021;30:38–49.

    Article  CAS  Google Scholar 

  3. Ariazi JL, Duffy KJ, Adams DF, Fitch DM, Luo L, Pappalardi M, Biju M, DiFilippo EH, Shaw T, Wiggall K, Erickson-Miller C. Discovery and preclinical characterization of GSK1278863 (daprodustat), a small molecule hypoxia-inducible factor-prolyl hydroxylase inhibitor for anemia. J Pharmacol Exp Ther. 2017;363:336–47.

    Article  CAS  Google Scholar 

  4. Astellas Pharma Inc. Pharmaceutical Interview Form Everenzo (Roxadustat). 6th edition, 2021. Japanese prescribing information. https://image.packageinsert.jp/pdf.php?mode=1&yjcode=3999047F1028. Accessed April 20, 2021.

  5. Kiriakidis S, Hoer SS, Burrows N, Biddlecome G, Khan MN, Thinnes CC, Schofield CJ, Rogers N, Botto M, Paleolog E, Maxwell PH. Complement C1q is hydroxylated by collagen prolyl 4 hydroxylase and is sensitive to off-target inhibition by prolyl hydroxylase domain inhibitors that stabilize hypoxia-inducible factor. Kidney Int. 2017;92:900–8.

    Article  CAS  Google Scholar 

  6. Vasta JD, Raines RT. Collagen prolyl 4-hydroxylase as a therapeutic target. J Med Chem. 2018;61:10403–11.

    Article  CAS  Google Scholar 

  7. Yeh TL, Leissing TM, Abboud MI, Thinnes CC, Atasoylu O, Holt-Martyn JP, Zhang D, Tumber A, Lippl K, Lohans CT, Leung IKH, Morcrette H, Clifton IJ, Claridge TDW, Kawamura A, Flashman E, Lu X, Ratcliffe PJ, Chowdhury R, Pugh CW, Schofield CJ. Molecular and cellular mechanisms of HIF prolyl hydroxylase inhibitors in clinical trials. Chem Sci. 2017;8:7651–68.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Kidney Disease and Dialysis Center, Hidaka Hospital, Hidaka-kai, 886 Nakao-machi, Takasaki, Gunma, 370-0001, Japan

    Nobuo Nagano

  2. Department of Medicine, Tokyo Women’s Medical University Medical Center East, Tokyo, Japan

    Nobuo Nagano

Authors
  1. Nobuo Nagano
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nobuo Nagano.

Ethics declarations

Conflict of interest

The author received lecture fees from Kyowa Kirin Co., Ltd., Torii Pharmaceutical Co., Ltd., and Nobelpharma Co., Ltd.

Human and animal rights

Not applicable as the article is the author’s personal opinion.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nagano, N. Selectivity of HIF-PH inhibitors: concerns regarding possible off-target effects. Clin Exp Nephrol 25, 1047–1048 (2021). https://doi.org/10.1007/s10157-021-02070-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10157-021-02070-3

Keywords

Search

Navigation